4Rebulla P. Refractoriness to platelet transfusion. Curt Opin Hematol, 2002, 9:516-520.
5Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FeRgamma-chain complex from the human platelet surface. Blood, 2004, 104:1350-1355.
6Chockalingam P, Sacher RA. Management of patients refractory to platelet transfusion. J Infus Nurs, 2007, 30:220-225.
7Slichter S J, Davis K Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood, 2005, 105: 4106-4114.
8Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood, 2004, 103:333-339.
9Campbell K, Rishi K, Howkins G, et al. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation. Vox Sang, 2007, 93:289-297.
10Killick SB, Win N, Marsh JC, et al. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia. Br J Haematol, 1997, 97:677-684.
5Bessos H, Wilson DW, Metcalfe P, et al. Report on the 12th international society of blood transfusion platelet immunology workshop. Vox Sanguinis,2005 ;89(2) :105 - 113.
8Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Onco1,2007 ; 19 ( 5 ) : 1519 - 1538.
9Hux BD,Martin LG. Platelet transfusions:treatment options for hemorrhage secondary to thrombocytopenia [J].J Vet Emerg Crit Care (San Antonio), 2012,22 ( 1 ) : 73-80.
10Vassallo RR.Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients [J]. Immunohematology, 2009,25(3) : 119-124.
